Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Seattle Cancer Care Alliance
0
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Seattle Cancer Care Alliance
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-Ballard Campus
2
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Ballard Campus
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center-First Hill
2
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-First Hill
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Center of Seattle
7
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Center of Seattle
7
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Shelton
45
mi
from 98109
Shelton, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Shelton
45
mi
from 98109
Shelton, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Rockwood Clinic Cancer Treatment Center-Valley
238
mi
from 98109
Spokane Valley, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Rockwood Clinic Cancer Treatment Center-Valley
238
mi
from 98109
Spokane Valley, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Evergreen Hematology and Oncology, PS
229
mi
from 98109
Spokane, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Evergreen Hematology and Oncology, PS
229
mi
from 98109
Spokane, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Rockwood Cancer Treatment Center-DHEC-Downtown
228
mi
from 98109
Spokane, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Rockwood Cancer Treatment Center-DHEC-Downtown
228
mi
from 98109
Spokane, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Franciscan Research Center-Northwest Medical Plaza
27
mi
from 98109
Tacoma, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Franciscan Research Center-Northwest Medical Plaza
27
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
27
mi
from 98109
Tacoma, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
27
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
PeaceHealth Southwest Medical Center
mi
from 98109
Vancouver, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Southwest Medical Center
mi
from 98109
Vancouver, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Saint Mary Regional Cancer Center
217
mi
from 98109
Walla Walla, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Saint Mary Regional Cancer Center
217
mi
from 98109
Walla Walla, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
North Star Lodge
109
mi
from 98109
Yakima, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
North Star Lodge
109
mi
from 98109
Yakima, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer System-Yelm
49
mi
from 98109
Yelm, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Yelm
49
mi
from 98109
Yelm, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Monongalia Hospital
2160
mi
from 98109
Morgantown, WV
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Monongalia Hospital
2160
mi
from 98109
Morgantown, WV
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation-Sunnyvale
667
mi
from 98109
Sunnyvale, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation-Sunnyvale
667
mi
from 98109
Sunnyvale, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Medical Center
1714
mi
from 98109
Bloomington, IL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Medical Center
1714
mi
from 98109
Bloomington, IL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
1680
mi
from 98109
Pekin, IL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
1680
mi
from 98109
Pekin, IL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
1672
mi
from 98109
Peoria, IL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
1672
mi
from 98109
Peoria, IL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
1678
mi
from 98109
Peoria, IL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
1678
mi
from 98109
Peoria, IL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Medical Oncology and Hematology Associates-West Des Moines
1455
mi
from 98109
Clive, IA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Medical Oncology and Hematology Associates-West Des Moines
1455
mi
from 98109
Clive, IA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Medical Oncology and Hematology Associates-Laurel
1462
mi
from 98109
Des Moines, IA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Medical Oncology and Hematology Associates-Laurel
1462
mi
from 98109
Des Moines, IA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Alegent Health Immanuel Medical Center
1358
mi
from 98109
Omaha, NE
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Alegent Health Immanuel Medical Center
1358
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
1184
mi
from 98109
Albuquerque, NM
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Hillcrest Hospital Cancer Center
2031
mi
from 98109
Mayfield Heights, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Hillcrest Hospital Cancer Center
2031
mi
from 98109
Mayfield Heights, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
1568
mi
from 98109
Tulsa, OK
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
1568
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Saint Vincent Medical Center
148
mi
from 98109
Portland, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Saint Vincent Medical Center
148
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Wellspan Health - York Cancer Center
2300
mi
from 98109
York, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Wellspan Health - York Cancer Center
2300
mi
from 98109
York, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
WellSpan Health-York Hospital
2300
mi
from 98109
York, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
WellSpan Health-York Hospital
2300
mi
from 98109
York, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Women and Infants Hospital
2487
mi
from 98109
Providence, RI
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Women and Infants Hospital
2487
mi
from 98109
Providence, RI
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
2080
mi
from 98109
Birmingham, AL
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
2080
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-Baldwin Park
963
mi
from 98109
Baldwin Park, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-Baldwin Park
963
mi
from 98109
Baldwin Park, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center
1055
mi
from 98109
La Jolla, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center
1055
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Mission
1062
mi
from 98109
San Diego, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Mission
1062
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego Zion
1061
mi
from 98109
San Diego, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego Zion
1061
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Marcos
1038
mi
from 98109
San Marcos, CA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Marcos
1038
mi
from 98109
San Marcos, CA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney and Lois Eskenazi Hospital
1867
mi
from 98109
Indianapolis, IN
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney and Lois Eskenazi Hospital
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Greater Regional Medical Center
1445
mi
from 98109
Creston, IA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greater Regional Medical Center
1445
mi
from 98109
Creston, IA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Chanute
1519
mi
from 98109
Chanute, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Chanute
1519
mi
from 98109
Chanute, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Dodge City
1315
mi
from 98109
Dodge City, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Dodge City
1315
mi
from 98109
Dodge City, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - El Dorado
1451
mi
from 98109
El Dorado, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - El Dorado
1451
mi
from 98109
El Dorado, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas - Fort Scott
1545
mi
from 98109
Fort Scott, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas - Fort Scott
1545
mi
from 98109
Fort Scott, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas-Independence
1525
mi
from 98109
Independence, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas-Independence
1525
mi
from 98109
Independence, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Kingman
1404
mi
from 98109
Kingman, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Kingman
1404
mi
from 98109
Kingman, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Lawrence Memorial Hospital
1478
mi
from 98109
Lawrence, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Lawrence Memorial Hospital
1478
mi
from 98109
Lawrence, KA
Click here to add this to my saved trials